1. The STRATA Study. Kidney Transplant 1. The STRATA Study (Study of Transplant-Related Anemia Treated with Aranesp) Source Bloom RD, Bolin P, Gandra.

Slides:

Advertisements

Similar presentations

Controlling for Time Dependent Confounding Using Marginal Structural Models in the Case of a Continuous Treatment O Wang 1, T McMullan 2 1 Amgen, Thousand.

Advertisements

The FREEDOM Study (Impact of Short Daily Hemodialysis on Restless Legs Symptoms and Sleep Disturbances) Source Jaber BL, Schiller B, Burkart JM, et al.

Pediatric Chronic Pain and Differences in Parental Health-Related Quality of Life Gustavo R. Medrano¹, Susan T. Heinze¹, Keri R. Hainsworth 2,3, Steven.

Neel Bhalala (2009) Sofia Medical University. Background  Erythropoiesis-stimulating agents are man-made versions of a natural protein known as erythropoietin.

ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.

1 Epoetin Alpha: FDA Overview of Patient Reported Outcome (PRO) Claims Ann Marie Trentacosti, M.D. Study Endpoints and Labeling Office of New Drugs Food.

Reference Avram MM, et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend.

Health-related quality of life in diabetic patients and controls without diabetes in refugee camps in Gaza strip: a cross-sectional study By: Ashraf Eljedi:

Self-Report Measures of Functional Status and Quality of Life: Adults Sandra A. Mitchell, CRNP, M.Sc.N., AOCN National Institutes of Health Bethesda, MD.

Peritoneal Dialysis for Elderly Patients: A Review Source: Tesar V. Peritoneal dialysis in the elderly—is its underutilization justified? Nephrol Dial.

Quality of Life in People with and at Risk for Type 2 Diabetes: Findings from the Study to Help Improve Early Evaluation and Management of Risk Factors.

Use of Health-Related Quality of Life Measures to Assess Individual Patients July 24, 2014 (1:00 – 2:00 PDT) Kaiser Permanente Methods Webinar Series Ron.

Exploring the SF-36, V2: Measuring the Quality of Life of AgrAbility Program Participants Ronald C. Jester Robert A. Wilson University of Delaware National.

Long-term functional deficiencies of ICU-acquired weakness: a prospective study I Patsaki, G Sidiras, V Gerovasili, A Kouvarakos, E Polimerou, G Mitsiou,

ERYTHROPOIESIS- STIMULATING AGENTS. Patients who are no longer able to produce enough erythropoietin in the kidneys may benefit from treatment with.

TREATMENT OF ANEMIA WITH DARBEPOETIN ALFA IN SYSTOLIC HEART FAILURE Karl Swedberg, M.D., Ph.D., James B. Young, M.D., Inder S. Anand, M.D., Sunfa Cheng,

The CONVERT Trial Source: Alberú J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based,

Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.

The Impact of Lifestyle Modification on the Health-Related Quality of Life of Patients With Reflux Esophagitis Receiving Treatment With a Proton Pump Inhibitor.

Erythropoietin for anemia of CRF.

Health Related Quality of Life after serious occupational injuries and long term disability Presenter: Ibishi Nazmie MD,PhD University Clinical Center.

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015

ALBUMIN IS AN EFFECT MODIFIER IN THE RELATIONSHIP BETWEEN ERYTHROPOIETIN STIMULATING AGENT AND MORTALITY IN HEMODIALYSIS PATIENTS. Satoshi Mikami1, Takayuki.

Darbepoetin alfa Drugbank ID : DB

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled.

PHASA Conference September 2016

The ALERT Trial.

CONCLUSIONS AND DISCUSSION

When Using DOPPS Slides

MRC Dementias Platform UK

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

University of Arkansas for Medical Sciences Little Rock, Arkansas

PHQ2 Screening Negative PHQ2 Screening Positive

CPR 1.1. Identifying Patients and Initiating Evaluation

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin.

Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Clinical Epidemiology and Global Health

A Six-hour Hemodialysis Without a Significant Increase in Dialysis Dose, as Judged by Kt/V, Can Reduce the Dosage of Erythropoietin Department of Kidney.

Ronald C. Jester Robert A. Wilson University of Delaware

Health-Related Quality-of-Life Measures: Evidence from Tunisian Population Using the SF-12 Health Survey Moheddine Younsi, PhD Value in Health Regional.

The Impact of Pain Management on Quality of Life

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled.

Greg A. Knoll, MD, MSc American Journal of Kidney Diseases

Darbepoetin alfa: A new therapeutic agent for renal anemia

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Clinical Epidemiology and Global Health

Seth D. Crockett, Quinn K. Lippmann, Evan S. Dellon, Nicholas J

American Journal of Kidney Diseases

Darbepoetin alfa (Aranesp™) in children with chronic renal failure

Francesco Locatelli, Lucia Del Vecchio Kidney International

Erratum American Journal of Kidney Diseases

Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.

Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia David E. Leaf, David S. Goldfarb Kidney.

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Anemia After Renal Transplantation

Erratum American Journal of Kidney Diseases

Mean individual and summative SF-36 V2 scores before and 3 months after ablation. Mean individual and summative SF-36 V2 scores before and 3 months after.

Volume 62, Issue 6, Pages (December 2002)

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

Spydergram of mean SF-36 domain scores at baseline and weeks 12 (A) and 24 (B) for sarilumab 150 mg and 200 mg+csDMARDs compared with placebo+csDMARDs.

Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment Ralf W. Sprengers, MD, Martin Teraa,

Spider plot of the unstandardised SF-36v2 subscales, comparing our HCM population with the mean for the general population (aged 45–54 years). Spider plot.

Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.

Evaluating the Significance of Individual Change

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Presentation transcript:

1. The STRATA Study

Kidney Transplant 1. The STRATA Study (Study of Transplant-Related Anemia Treated with Aranesp) Source Bloom RD, Bolin P, Gandra SR, et al. Impact on health-related quality of life in kidney transplant recipients with late posttransplant anemia administered darbepoetin alfa: results from the STRATA study. Transplant Proc. 2011;43(5):1593–1600.

Background In patients with end-stage renal disease, anemia is a common complication. In most cases, anemia improves after renal transplantation, usually within the first 3 months. Post-transplant anemia is, however, highly prevalent (30–40%). Anemia is believed to have a substantial negative impact on the health-related quality of life (HRQOL) and includes lethargy and sleep disturbance. Darbepoetin alfa (Aranesp, Amgen Inc, Thousand Oaks, CA, USA) is an ESA with the same mechanism of action as recombinant human erythropoietin but has a longer half-life as well as greater biological activity.

Aim To assess the effect of darbepoetin alfa administered subcutaneously on hemoglobin and HRQOL.

Methods

Summary of key results Increase in mean hemoglobin concentration from 9.9 (1.2) g/dL at baseline to 11.7 (1.3) g/dL during the evaluation period. Significant improvement in physical component summary (PCS), physical functioning, limitations due to physical health, bodily pain, limitations due to emotion health, and vitality scores seen with darbepoetin alfa use. SF-36 sub-scales and component summary scores were lower in subjects with baseline Hb <10 g/dL than in subjects with Hb ≥10 g/dL. Statistically significant improvement observed for all subjects in physical component summary (0.5 points, P<0.001), physical functioning (11.8 points, P=0.001), limitations due to physical health (26.5 points, P<0.001), bodily pain (7.7 points, P=0.01), limitations due to emotional health (15.7 points, P=0.01), and vitality (12.8 points, P<0.001) from baseline to week 24 following treatment with darbepoetin alfa.

Conclusion This study indicates that the patients with post-transplant anemia have lower HRQOL than the general population. Improvement in HRQOL and levels of hemoglobin was seen with treatment with darbepoetin alfa. In patients undergoing kidney transplant with PTA, darbepoetin alfa significantly increased Hb concentrations and improved HRQOL scores.